Thanks, Mr. Chair.
This has been incredibly powerful testimony. I want to thank the witnesses again.
I want to go back to the issue of informed decision-making of servicewomen and servicemen taking mefloquine.
According to the American Society of Health-System Pharmacists, mefloquine is contraindicated for individuals with a recent history of psychiatric disorders. Given that service women and men are potentially out in the field experiencing events that can be traumatic, how could we continue to give out this drug? As has been pointed out earlier, 5% of servicemen and servicewomen in this country are taking this drug.
How are we able to give them that informed decision-making if they are put in circumstances that could potentially create situations where they are being exposed to trauma and very challenging situations that increase their risk of the adverse side effects of this medication?